The early stage of vascular dementia: significance of a complete therapeutic program

2003 ◽  
Vol 18 (5) ◽  
pp. 402-406 ◽  
Author(s):  
L. S. Kruglov
Keyword(s):  
Vascular Dementia ◽  
Early Stage ◽  
Therapeutic Program

Preclinical Cognitive Trajectories Differ for Alzheimer's Disease and Vascular Dementia

2012 ◽  
Vol 18 (2) ◽  
pp. 191-199 ◽  
Author(s):  
Erika J. Laukka ◽  
Stuart W.S. MacDonald ◽  
Laura Fratiglioni ◽  
Lars Bäckman
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vascular Dementia ◽  
Early Stage ◽  
Block Design ◽  
Word Recall ◽  
Cognitive Tasks ◽  
Control Group ◽  
Age Related ◽  
Preclinical Ad

AbstractWe investigated differences between Alzheimer's disease (AD) and vascular dementia (VaD) from the appearance of the first cognitive symptoms, focusing on both time of onset and rate of accelerated decline for different cognitive functions before dementia diagnosis. Data from a longitudinal population-based study were used, including 914 participants (mean age = 82.0 years, SD = 5.0) tested with a cognitive battery (word recall and recognition, Block Design, category fluency, clock reading) on up to four occasions spanning 10 years. We fit a series of linear mixed effects models with a change point to the cognitive data, contrasting each dementia group to a control group. Significant age-related decline was observed for all five cognitive tasks. Relative to time of diagnosis, the preclinical AD persons deviated from the normal aging curve earlier (up to 9 years) compared to the preclinical VaD persons (up to 6 years). However, once the preclinical VaD persons started to decline, they deteriorated at a faster rate than the preclinical AD persons. The results have important implications for identifying the two dementia disorders at an early stage and for selecting cognitive tasks to evaluate treatment effects for persons at risk of developing AD and VaD. (JINS, 2012, 18, 191–199)

The Differential Cognitive Deficits Between Patients with Early Stage Alzheimer's Disease and Patients with Early Stage Vascular Dementia

2017 ◽  
Vol 41 (S1) ◽  
pp. S175-S175 ◽  
Author(s):  
J.H. Park ◽  
K. Kyung Min ◽  
J. Byoung Sun
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vascular Dementia ◽  
Cognitive Deficits ◽  
Processing Speed ◽  
Comprehensive Evaluation ◽  
Early Stage ◽  
Word List ◽  
Clinical Dementia Rating ◽  
Korean Version

BackgroundThe study aims to examine whether cognitive deficits are different between patients with early stage Alzheimer's disease (AD) and patients with early stage vascular dementia (VaD) using the Korean version of the CERAD neuropsychological battery (CERAD-K-N).MethodsPatients with early stage dementia, global Clinical Dementia Rating (CDR) 0.5 or 1 were consecutively recruited among first visitors to a dementia clinic, 257 AD patients and 90 VaD patients completed the protocol of the Korean version of the CERAD clinical assessment battery. CERAD-K-N was administered for the comprehensive evaluation of the neuropsychological function.ResultsOf the total 347 participants, 257 (69.1%) were AD group (CDR 0.5 = 66.9%) and 90 (21.9%) were VaD group (CDR 0.5 = 40.0%). Patients with very mild AD showed poorer performances in Boston naming test (BNT) (P = 0.028), word list memory test (P < 0.001), word list recall test (P < 0.001) and word list recognition test (WLRcT) (P = 0.006) than very mild VaD after adjustment of T score of MMSE-KC. However, the performance of trail making A (TMA) was more impaired in VaD group than in AD group. The performance of WLRcT (P < 0.001) was the worst among neuropsychological tests within AD group, whereas TMA was performed worst within VaD group.ConclusionsPatients with early-stage AD have more cognitive deficits on memory and language while patients with early-stage VaD show worse cognitive function on attention/processing speed. In addition, as the first cognitive deficit, memory dysfunction comes in AD and deficit in attention/processing speed in VaD.Disclosure of interestThe authors have not supplied their declaration of competing interest.

NEUROPSYCHOLOGICAL EVALUATION OF NARRATIVE DISCOURSE PATTERNS IN INDIVIDUALS WITH EARLY STAGE VASCULAR DEMENTIA VS. PATIENTS WITH EARLY STAGE ALZHEIMER’S DISEASE

2021 ◽  
Vol 19 (2) ◽  
pp. 187-207
Author(s):  
Natalia Gawron ◽  
Emilia Łojek ◽  
Beata Hintze ◽  
Anna Rita Egbert
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vascular Dementia ◽  
Fairy Tales ◽  
Verbal Memory ◽  
Fairy Tale ◽  
Early Stage ◽  
Narrative Discourse ◽  
Language Difficulties ◽  
And Control

Individuals in the early stages of dementia may demonstrate language difficulties. The aim of the study was an evaluation of the differences in narrative discourse abilities across two types of dementia, i.e., Vascular Dementia (VaD) and Alzheimer’s Disease (AD) in comparison to the young and old elderly. The AD and VaD groups displayed a lower performance than the age-matched YE on tasks involving reasoning. The VaD partici- pants outperformed patients with AD in verbal memory and narrative discourse. Discourse macrostructure analyses showed that the VaD reproduced more propositions than did the AD participants, but that these were comparable to YE and OE. There were more conjunctions in narratives reproduced by the VaD participants as compared to other groups, although this tendency was only present in the story but not in fairy tale reproductions themselves. Individ- uals in the AD group had more difficulties than YE and OE individuals in figuring out the moral of fairy tales. Clinical and control groups reproduced the microstructure and superstructure of texts comparatively well. Discourse recall correlated with performance on verbal memory, attention/working memory, and reasoning. Differences in narrative discourse abilities were found. Alzheimer’s Disease (AD) patients scored lower in verbal memory than did Vascular Dementia (VaD) patients. Both groups however obtained lower results than the young and old elderly.

scholarly journals ReCODE: A Personalized, Targeted, Multi-Factorial Therapeutic Program for Reversal of Cognitive Decline

Biomedicines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1348
Author(s):  
Rammohan V Rao ◽  
Sharanya Kumar ◽  
Julie Gregory ◽  
Christine Coward ◽  
Sho Okada ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cognitive Impairment ◽  
Cognitive Decline ◽  
Early Stage ◽  
Treatment Strategies ◽  
High Sensitivity ◽  
Rank Test ◽  
Proof Of Concept ◽  
Therapeutic Program

Background: Alzheimer’s disease (AD) is the major cause of age-associated cognitive decline, and in the absence of effective therapeutics is progressive and ultimately fatal, creating a dire need for successful prevention and treatment strategies. We recently reported results of a successful proof-of-concept trial, using a personalized, precision medicine protocol, but whether such an approach is readily scalable is unknown. Objective: In the case of AD, there is not a single therapeutic that exerts anything beyond a marginal, unsustained, symptomatic effect. This suggests that the monotherapeutic approach of drug development for AD may not be an optimal one, at least when used alone. Using a novel, comprehensive, and personalized therapeutic system called ReCODE (reversal of cognitive decline), which proved successful in a small, proof-of-concept trial, we sought to determine whether the program could be scaled to improve cognitive and metabolic function in individuals diagnosed with subjective cognitive impairment, mild cognitive impairment, and early-stage AD. Methods: 255 individuals submitted blood samples, took the Montreal Cognitive Assessment (MoCA) test, and answered intake questions. Individuals who enrolled in the ReCODE program had consultations with clinical practitioners, and explanations of the program were provided. Participants had follow-up visits that included education regarding diet, lifestyle choices, medications, supplements, repeat blood sample analysis, and MoCA testing between 2 and 12 months after participating in the ReCODE program. Pre- and post-treatment measures were compared using the non-parametric Wilcoxon signed rank test. Results and Conclusions: By comparing baseline to follow-up testing, we observed that MoCA scores either significantly improved or stabilized in the entire participant pool—results that were not as successful as those in the proof-of-concept trial, but more successful than anti-amyloid therapies—and other risk factors including blood glucose, high-sensitivity C-reactive protein, HOMA-IR, and vitamin D significantly improved in the participant pool. Our findings provide evidence that a multi-factorial, comprehensive, and personalized therapeutic program designed to mitigate AD risk factors can improve risk factor scores and stabilize or reverse the decline in cognitive function. Since superior results were obtained in the proof-of-concept trial, which was conducted by a small group of highly trained and experienced physicians, it is possible that results from the use of this personalized approach would be enhanced by further training and experience of the practicing physicians. Nonetheless, the current results provide further support indicating the potential of such an approach for the prevention and reversal of cognitive decline.

P2-316: THE PATTERNS OF COGNITIVE DYSFUNCTION OF PATIENTS WITH ALZHEIMER'S DISEASE AND WITH VASCULAR DEMENTIA AT EARLY STAGE OF DEMENTIA

2006 ◽  
Vol 14 (7S_Part_15) ◽  
pp. P803-P803
Author(s):  
Hyun-ju Yang ◽  
Joon Hyuk Park ◽  
Byoung Sun Jun ◽  
Kyung Min Kim
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vascular Dementia ◽  
Cognitive Dysfunction ◽  
Early Stage

Mismatch negativity as a potential neurobiological marker of early-stage Alzheimer disease and vascular dementia

2017 ◽  
Vol 647 ◽  
pp. 26-31 ◽  
Author(s):  
Shixiang Jiang ◽  
Chang Yan ◽  
Zhengxue Qiao ◽  
Haiqian Yao ◽  
Shiquan Jiang ◽  
...  
Keyword(s):  
Alzheimer Disease ◽  
Vascular Dementia ◽  
Mismatch Negativity ◽  
Early Stage

scholarly journals MR MORPHOMERY OF THE HIPPOCAMPUS IN NORMAL VOLUNTEERS AND PATIENTS WITH PSYHOTIC DISORDERS DISEASE

2019 ◽  
pp. 50-58
Author(s):  
N. I. Ananyeva ◽  
E. V. Andreev ◽  
T. A. Salomatina ◽  
L. R. Akhmerova ◽  
R. V. Ezhova ◽  
...  
Keyword(s):  
Vascular Dementia ◽  
Hippocampal Formation ◽  
Early Stage ◽  
Psychiatric Diseases ◽  
Normal Volunteers ◽  
Mri Morphometry ◽  
Hippocampal Activity ◽  
Affective Functioning ◽  
The Brain

Role of limbic system, first of all, hippocampal formation, is carefully analyzed in literature because of its involvement in different psychiatric diseases. Results are contradictory, may be because of insufficient data of normal volumes of structures involving in cognitive and affective functioning of the brain. Hippocampus is very complex organized structure consisting of different subfields and subregions which probably differently changes in different psychiatric diseases. Aim of our study was to analyzed changes in volumes of the whole hippocampus, its subregions and subfields in different psychiatric diseases. In our study we have analyzed MRI morphometry of hippocampal formation in healthy volunteers, patients with Alzheimerdisease (AD) in early stage, vascular dementia (VD), depression based on medical literatureandourexperience. Patients were divided on 4 groups: 10 patients with early Alzheimer disease, 10 normal volunteers, 10 patients with vascular dementia and 10 patients with depression. We have determined method of definition and volume evaluation of different hippocampal subfields. We find difference in the volumes of CA3, molecular stratum and fascia dentatain early stage of AD; in the volume of hippocampal tail, molecular stratum of fascia dentataand CA3 in patients with VD; in molecular stratum of fasciadentata, fimbria and CA3 in patients with depression because of role of these fields in coordination of hippocampal activity.

Sign in / Sign up

Export Citation Format

Share Document